Over 90% of males exhibit hyperglycemia of >250 mg/dl by 20 weeks of age. Body weight in males increases to 55 gm by 16 weeks of age. The diabetic phenotype is very similar to that of NZO/HlLt J (Stock No. 002105) mice. An advantage of NZL/LtJ over NZO/HlLtJ as a diabetes model, in addition to the higher disease incidence, is that mice of this strain breed well, whereas NZO/HlLt mice breed very poorly.
This strain carries the wildtype Ighm allele from the NZO/HlLtJ strain.
This strain was developed in parallel with NZL.129S2-Ighmtm1Cgn/Lt. The Ighmtm1Cgn targeted allele was obtained by Dr. Edward Leiter at N11 on the NZB/Hl background, to which it had been transferred from B6.129S2-Ighmtm1Cgn. In Dr. Leiter's laboratory, the mutation was backcrossed onto the NZO/HlLt strain for 5 generations. The N5 Ighmtm1Cgn heterozygotes were intercrossed, and two sublines were initiated from the progeny: Mice homozygous for the targeted mutation were selected to generate a homozygous Ighmtm1Cgn line, and mice homozygous for the wildtype Ighm allele were chosen to start a parallel wildtype line.
As backcrossing was carried out for only 5 generations, the genome of these strains is, statistically, approximately 3.12% of NZB origin with known genetic regions on chromosones 9 and 18; there may also be minor contributions from C57BL/6 and 129S2/SvPas. The control line was found to have a severe diabetes phenotype comparable to that of the NZO/HlLt background strain, but to have certain advantages over the latter. For this reason, the new line was assigned its own inbred-strain nomenclature once it had reached the equivalent of 20 generations of sibling inbreeding.
This strain was donated to The Jackson Laboratory in 2004.
Currently there are no related genes or alleles for this strain.